Compile Data Set for Download or QSAR
Report error Found 1533 Enz. Inhib. hit(s) with all data for entry = 10464
TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537421(US11247990, Example 246 | (R)-3-(4-(1-((1s,4S)-4-(...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537421(US11247990, Example 246 | (R)-3-(4-(1-((1s,4S)-4-(...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537422(US11247990, Example 247 | (R)-1-(4-(6-(ethylamino)...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537422(US11247990, Example 247 | (R)-1-(4-(6-(ethylamino)...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537423(US11247990, Example 248 | 2-(4-(6-(ethylamino)-1-(...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM537422(US11247990, Example 247 | (R)-1-(4-(6-(ethylamino)...)
Affinity DataIC50: 20nMAssay Description:TYRO3: Compounds of Formula I were screened for their ability to inhibit TYRO3 kinase using Invitrogen's LanthaScreen Eu Kinase Binding technolog...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM537423(US11247990, Example 248 | 2-(4-(6-(ethylamino)-1-(...)
Affinity DataIC50: 20nMAssay Description:TYRO3: Compounds of Formula I were screened for their ability to inhibit TYRO3 kinase using Invitrogen's LanthaScreen Eu Kinase Binding technolog...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537423(US11247990, Example 248 | 2-(4-(6-(ethylamino)-1-(...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM537414(US11247990, Example 239 | (2S,3S)-1-(4-(6- (ethyla...)
Affinity DataIC50: 20nMAssay Description:TYRO3: Compounds of Formula I were screened for their ability to inhibit TYRO3 kinase using Invitrogen's LanthaScreen Eu Kinase Binding technolog...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537416(US11247990, Example 241 | (R)-3-(4-(6-(ethylamino)...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537431(US11247990, Example 256 | 5-(6-(ethylamino)-1-((1s...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537431(US11247990, Example 256 | 5-(6-(ethylamino)-1-((1s...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537432(US11247990, Example 257 | 5-(6-(ethylamino)-1-((1s...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537432(US11247990, Example 257 | 5-(6-(ethylamino)-1-((1s...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537433(US11247990, Example 258 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM537433(US11247990, Example 258 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:TYRO3: Compounds of Formula I were screened for their ability to inhibit TYRO3 kinase using Invitrogen's LanthaScreen Eu Kinase Binding technolog...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537433(US11247990, Example 258 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537434(US11247990, Example 259 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537434(US11247990, Example 259 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537435(US11247990, Example 260 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537435(US11247990, Example 260 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537430(US11247990, Example 255 | tert-butyl ethyl(1-((1s,...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537430(US11247990, Example 255 | tert-butyl ethyl(1-((1s,...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537441(US11247990, Example 266 | 5-(1-((1s,4s)-4-((1-meth...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537443(US11247990, Example 268 | N-ethyl-1-((1s,4s)-4-((3...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537443(US11247990, Example 268 | N-ethyl-1-((1s,4s)-4-((3...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537444(US11247990, Example 269 | N-ethyl-1-((1s,4s)-4-((3...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537446(US11247990, Example 271 | 3-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537446(US11247990, Example 271 | 3-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537436(US11247990, Example 261 | N-ethyl-1-((1s,4s)-4-((3...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537436(US11247990, Example 261 | N-ethyl-1-((1s,4s)-4-((3...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537437(US11247990, Example 262 | N-methyl-3-(1-methyl-1H-...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537437(US11247990, Example 262 | N-methyl-3-(1-methyl-1H-...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537438(US11247990, Example 263 | 2-methyl-2-(4-(1-((1s,4s...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537438(US11247990, Example 263 | 2-methyl-2-(4-(1-((1s,4s...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537439(US11247990, Example 264 | N-methyl-1-((1s,4s)-4-((...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537439(US11247990, Example 264 | N-methyl-1-((1s,4s)-4-((...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537441(US11247990, Example 266 | 5-(1-((1s,4s)-4-((1-meth...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537454(US11247990, Example 279 | N-ethyl-3-(1-methyl-1H- ...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537454(US11247990, Example 279 | N-ethyl-3-(1-methyl-1H- ...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537455(US11247990, Example 280 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM537454(US11247990, Example 279 | N-ethyl-3-(1-methyl-1H- ...)
Affinity DataIC50: 20nMAssay Description:TYRO3: Compounds of Formula I were screened for their ability to inhibit TYRO3 kinase using Invitrogen's LanthaScreen Eu Kinase Binding technolog...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM537455(US11247990, Example 280 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:TYRO3: Compounds of Formula I were screened for their ability to inhibit TYRO3 kinase using Invitrogen's LanthaScreen Eu Kinase Binding technolog...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537455(US11247990, Example 280 | 2-(4-(6-(ethylamino)-1- ...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537447(US11247990, Example 272 | (1R,4r)-4-(4-(6-(ethylam...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537447(US11247990, Example 272 | (1R,4r)-4-(4-(6-(ethylam...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor UFO(Human)
Array Biopharma

US Patent
LigandPNGBDBM537463(US11247990, Example 288 | 5-(6-(ethylamino)-1- ((1...)
Affinity DataIC50: 20nMAssay Description:AXL: Compounds of Formula I were screened for their ability to inhibit AXL kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM537462(US11247990, Example 287 | 6-(6-(ethylamino)-1-((1s...)
Affinity DataIC50: 20nMAssay Description:TYRO3: Compounds of Formula I were screened for their ability to inhibit TYRO3 kinase using Invitrogen's LanthaScreen Eu Kinase Binding technolog...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase receptor TYRO3(Human)
Array Biopharma

US Patent
LigandPNGBDBM537463(US11247990, Example 288 | 5-(6-(ethylamino)-1- ((1...)
Affinity DataIC50: 20nMAssay Description:TYRO3: Compounds of Formula I were screened for their ability to inhibit TYRO3 kinase using Invitrogen's LanthaScreen Eu Kinase Binding technolog...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

TargetTyrosine-protein kinase Mer(Human)
Array Biopharma

US Patent
LigandPNGBDBM537463(US11247990, Example 288 | 5-(6-(ethylamino)-1- ((1...)
Affinity DataIC50: 20nMAssay Description:MER: Compounds of Formula I were screened for their ability to inhibit MER kinase using Invitrogen's LanthaScreen Eu Kinase Binding technology. H...More data for this Ligand-Target Pair
In Depth
Date in BDB:
6/13/2022
Entry Details
Go to US Patent

Displayed 1 to 50 (of 1533 total ) | Next | Last >>
Jump to: